Project Grant 20246701842461
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $377,986 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Northern Colorado. The grant funds a 3-year research project to evaluate the therapeutic effects of the non-psychoactive cannabinoids cannabigerol (CBG) with or without cannabidiol (CBD) in alleviating the symptoms of diet-induced non-alcoholic fatty liver disease (NAFLD) and...
- GRANT AWARD SUMMARY The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under its Alcohol Research Programs (CFDA 93.273), awarded a $3.18 million Project Grant to the University of California, San Diego on September 20, 2025, with a completion date of August 31, 2029. This research project investigates the role of intestinal proteases, specifically cathepsin B (CTSB), in alcohol-associated liver disease (ALD). The project delivers comprehensive scientific research services including...
- Federal Grant Award Summary Oklahoma State University received a $551,696 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 12, 2025, with a completion date of August 31, 2028. The award funds basic biomedical research investigating the role of the cannabinoid 1 receptor (CB1R) in age-associated metabolic dysfunction-associated...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $2,999,512 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2029. This award supports fundamental biomedical research investigating the regulation of mitochondrial health in mammalian livers, with the...
- Federal Project Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $161,000 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), effective September 15, 2025, with an ultimate completion date of August 31, 2027. This research initiative focuses on elucidating the metabolic basis of sarcopenia in alcohol-related liver disease (ALD), specifically...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $177,736 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) on September 5, 2025, with a completion date of August 31, 2030. The award supports research investigating the role of hepatokines—liver-secreted proteins—in alcohol-associated hepatitis (AH) and alcohol-associated liver disease (ALD). The research project will examine...
- Federal Grant Award Summary The Medical University of South Carolina received a $1.98 million Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, effective September 1, 2025, through August 31, 2029, supports research and development of advanced fibrosis detection methodologies and a predictive diagnostic model for Metabolic Dysfunction-Associated...
- Federal Grant Award Summary The University of Tennessee Health Science Center received a $404,250 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded September 23, 2025, with completion targeted for August 31, 2027. The grant supports fundamental research investigating the role of margaric acid in mitigating alcohol-associated liver disease (AALD), a major global health burden accounting for over 5 percent...
- The University of Pittsburgh received a $100,228 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective December 8, 2026, through April 14, 2029. This award supports basic biomedical research investigating the role of hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease (MASLD), a condition affecting approximately...
- Federal Project Grant Award Summary Yale University received a $253,383 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded on September 10, 2025, with completion targeted for August 31, 2027. The grant funds research investigating the role of hepatocyte inflammasomes in alcoholic-associated liver disease (AALD), a leading cause of liver-related deaths in the United States. The research employs genetic mouse...
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS THE MOST COMMON CAUSE OF LIVER DISEASE IN THE UNITED STATES, AFFECTING APPROXIMATELY 80 MILLION ADULTS. IMPORTANTLY, RISK FACTORS FOR THE DEVELOPMENT OF NAFLD TEND TO INCREASE IN PREVALENCE WITH ADVANCING AGE. THE PATHOGENESIS OF NAFLD HAS BEEN CONSIDERED AS DEVELOPING FROM PREVALENT MULTIPLE PARALLEL FACTORS, INCLUDING GUT-LIVER AXIS, INFLAMMATORY PATHWAYS, AND THE HIGH-FAT WESTERN DIETS. NAFLD DISPLAYS KEY CHARACTERISTICS, SUCH AS INTESTINAL DYSBIOSIS AND GUT PERMEABILITY. IDENTIFICATION OF PREVIOUSLY UNRECOGNIZED MOLECULES CONTRIBUTING TO NAFLD VIA GUT-LIVER AXIS WILL HELP TO UNDERSTAND THE ACTION MECHANISMS FURTHER AND TO DEVELOP EFFICIENT PREVENTION STRATEGIES. GROWING EVIDENCE INDICATES THAT THE ENDOCANNABINOID SYSTEM (ECS) IS INTIMATELY INVOLVED IN THE DEVELOPMENT OF OBESITY AND TYPE 2 DIABETES (T2D), THE EARLIEST METABOLIC DRIVER OF NAFLD, MAINLY BY ACTIVATING THE CANNABINOID 1 RECEPTOR (CB1R) TO TARGET CENTRAL AND PERIPHERAL SITES SUCH AS THE LIVER. THE PREVIOUS STUDIES DISCOVERED THAT L-THEANINE, A NON-PROTEIN WATER-SOLUBLE AMINO ACID CHARACTERISTICALLY FOUND IN TEA PLANTS, CAN BIND TO CB1R AND INHIBIT ITS ACTIVITY. THUS, THE OBJECTIVE OF THIS PROJECT IS TO DETERMINE THE ROLE OF CB1R VIA GUT-LIVER AXIS IN THE TEA BIOACTIVITIES. THE RESULTS OF THIS PROJECT WILL HAVE SIGNIFICANT IMPLICATIONS BY PROVIDING FUNDAMENTAL GUIDELINES AND JUSTIFICATION FOR DEVELOPMENT OF FUTURE PROJECTS EXAMINING THE EFFECTS OF FOOD AND GUT HEALTH ON NAFLD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $300.0k | 5/16/24 |